Current Report Filing (8-k)
December 01 2020 - 5:04PM
Edgar (US Regulatory)
0000887247
false
0000887247
2020-12-01
2020-12-01
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event
reported): December 1, 2020
ADAMIS
PHARMACEUTICALS CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware
|
0-26372
|
82-0429727
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
11682 El Camino Real, Suite 300
San Diego, CA
|
92130
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (858) 997-2400
(Former name or Former Address, if Changed
Since Last Report.)
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Exchange Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock
|
|
ADMP
|
|
NASDAQ
Capital Market
|
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
On December 1, 2020, Adamis Pharmaceuticals
Corporation (“Adamis” or the “Company”) issued a press release announcing the Company’s planned response
to the Complete Response Letter (“CRL”) that the Company received in November 13, 2020, from the U.S. Food & Drug
Administration (“FDA”) regarding the Company’s resubmitted New Drug Application (“NDA”) for its ZIMHI™
high-dose naloxone injection product for the treatment of opioid overdose.
A copy of the Company’s
press release is attached hereto as Exhibit 99.1 and is incorporated into this item by reference.
Forward Looking Statements
This Current Report on Form 8-K
contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements include those that express plans, anticipation, intent, contingencies, goals, targets or future development and/or
otherwise are not statements of historical fact. These statements relate to future events or future results of operations, including,
but not limited to the following statements: the company’s beliefs concerning its ability to satisfactorily respond to the
matters raised in the FDA’s CRL; the company’s beliefs concerning the information, data and actions that the FDA may
require in connection with any resubmitted NDA relating to ZIMHI; the company’s beliefs concerning the timing and outcome
of any appeal and FDA formal dispute resolution process that the company may initiate; the company’s beliefs concerning
the results of any future studies or clinical trials that the company may conduct relating to ZIMHI; the company’s beliefs
concerning the timing and outcome of the FDA’s review of the company’s NDA relating to the ZIMHI product or any resubmitted
NDA; the company’s beliefs concerning its ability to commercialize ZIMHI and its other products and product candidates;
the company's beliefs concerning the ability of its product candidates to compete successfully in the market; the company's beliefs
concerning the safety and effectiveness of ZIMHI or its other products and product candidates; the company’s beliefs concerning
its commercialization strategies; and the company’s beliefs concerning the anticipated timing of any commercial launch of
its ZIMHI product. These statements are only predictions and involve known and unknown risks, uncertainties and other factors,
which may cause Adamis' actual results to be materially different from these forward-looking statements. The FDA may require additional
studies or other actions, data or information, prior to any resubmission of the NDA. There can be no assurances that the company
will be able to satisfactorily respond to the matters raised in the FDA’s CRL or concerning the timing of any resubmission
by us of the NDA responding to the CRL, concerning the timing or costs of any additional actions that may be required in connection
with any resubmission of the NDA, that the FDA will approve any resubmitted NDA relating to our ZIMHI product or concerning the
timing of any future action by the FDA on our NDA, that the company will be successful in any formal dispute resolution appeal
process with the FDA, or that the product will be able to compete successfully in the market if approved and launched. In addition,
forward-looking statements concerning our anticipated future activities assume that we are able to obtain sufficient funding to
support such activities and continue our operations and planned activities. As discussed in our filings with the Securities
and Exchange Commission, we will require additional funding, and there are no assurances that such funding will be available if
required. You should not place undue reliance on any forward-looking statements. Further, any forward-looking statement
speaks only as of the date on which it is made, and except as may be required by applicable law, we undertake no obligation to
update or release publicly the results of any revisions to these forward-looking statements or to reflect events or circumstances
arising after the date of this Report. Certain of these risks, uncertainties, and other factors are described in greater detail
in Adamis’ filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which
are available free of charge on the SEC's web site at http://www.sec.gov.
Except to the extent required by law, any forward-looking statements in this Report speak only as the date of this Report, and
Adamis expressly disclaims any obligation to update any forward-looking statements.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
99.1 Press
release dated December 1, 2020.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ADAMIS PHARMACEUTICALS CORPORATION
|
|
|
|
|
|
|
|
|
|
Dated: December 1, 2020
|
By:
|
/s/ Robert O. Hopkins
|
|
Name:
|
Robert O. Hopkins
|
|
Title:
|
Chief Financial Officer
|
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Historical Stock Chart
From Apr 2023 to Apr 2024